Short answer
CareDx, Inc. (CDNA) filed its Q1 2026 10-Q quarterly report on Apr 28, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $118M (up 39.0% year over year) with net income of $3M.
Q1 2026 key financials · XBRL
- Revenue
- $118M
- +39.0% YoY
- Net income
- $3M
- +127.1% YoY
- Operating margin
- 1.0%
- EPS (diluted)
- $0.05
- +126.3% YoY
Source: XBRL data from the CareDx, Inc. (CDNA) Q1 2026 10-Q on SEC EDGAR. USD.
CareDx, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Newly triggered PAMA compliance: private-payor rates from January–June 2025 reportable to CMS May–July 2026
- Medicare reimbursement risk: Proposed LCD may add coverage criteria, utilization limits, and bundled payments for CareDx testing
- Financial concentration: Medicare represented 35% of testing-services revenue for AlloSure and HeartCare tests
- Profitability risk: accumulated deficit $732.5 million despite $2.8 million first-quarter net income
- Competitive risk: Natera and Eurofins commercial molecular diagnostics compete in post-transplant surveillance
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other CareDx, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.